Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by herceptin in SKBR-3 human breast cancer cells

Experimental and Therapeutic Medicine

Volumn 1, Issue 3, 2010, Pages 513-518

  Sun, Yuan Wan ^a   Niu, Ting Kuang ^a   Yang, Jin Ming ^a   Kwon, Chul Hoon ^b   Chen, Kuen Yuan ^c   Chen, Kun Ming ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

9 aminoacridines; Apoptosis; Autophagy; HER2; Topoisomerase II

Indexed keywords

2 [[4 [4 (ACRIDIN 9 YLAMINO)PHENYLTHIO]PHENYL](2 HYDROXYETHYL)AMINO]ETHAN 1 OL; AMINOACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; CK 0402; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE;

EID: 77956211456     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000081     Document Type: Article

References (28)

1. Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19: 670-686, 1992.
2. Gianni L and Valagussa P: Anthracyclines and early breast cancer: the end of an era? J Clin Oncol 27: 1155-1157, 2009.
3. O'Shaughnessy J: Liposomal anthracyclines for breast cancer: overview. Oncologist 8 (Suppl 2): 1-2, 2003.
4. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
5. Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9: 338-350, 2009.
6. Shan K, Lincoff AM and Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47-58, 1996.
7. Chen KM, Sun YW, Tang YW, Sun ZY and Kwon CH: Synthesis and antitumor activity of sulfur-containing 9-anilinoacridines. Mol Pharm 2: 118-128, 2005.
8. Park SK, Kang H and Kwon CH: Caspase-dependent cell death mediates potent cytotoxicity of sulfide derivatives of 9-anilinoacridine. Anticancer Drugs 19: 381-389, 2008.
9. Baguley BC, Holdaway KM and Fray LMLM: Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst 82: 398-402, 1990.
10. Jarvinen TA and Liu ET: Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes - molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6: 579-602, 2006.
11. Jorgensen JT, Nielsen KV and Ejlertsen B: Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist 12: 397-405, 2007.
12. Smith I and Chua S: Medical treatment of early breast cancer. IV: neoadjuvant treatment. BMJ 332: 223-224, 2006.
13. Nahta R and Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138, 2006.
14. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
15. Smith K, Houlbrook S, Greenall M, Carmichael J and Harris AL: Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8: 933-938, 1993.
16. Amaravadi RK and Thompson CB: The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13: 7271-7279, 2007.
17. Klionsky DJ, Abeliovich H, Agostinis P, et al: Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175, 2008.
18. Baldwin EL and Osheroff N: Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5: 363-372, 2005.
19. Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS and Marks JR: Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res 18: 2919-2932, 1998.
20. Houlbrook S, Addison CM, Davies SL, et al: Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72: 1454-1461, 1995.
21. Mano MS, Rosa DD, De Azambuja E, Ismael GF and Durbecq V: The 17q12-q21 amplicon: Her2 and topoisomerase-IIIIalpha and their importance to the biology of solid tumours. Cancer Treat Rev 33: 64-77, 2007.
22. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F and Dhesy-Thind B: HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26: 736-744, 2008.
23. Haldane A, Holdaway KM, Finlay GJ and Baguley BC: Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin. Cancer Chemother Pharmacol 32: 463-470, 1993.
24. Morse DL, Gray H, Payne CM and Gillies RJ: Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4: 1495-1504, 2005.
25. Bursch W, Ellinger A, Gerner C, Frohwein U and Schulte-Hermann R: Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? Ann NY Acad Sci 926: 1-12, 2000.
26. Hoyer-Hansen M and Jaattela M: Autophagy: an emerging target for cancer therapy. Autophagy 4: 574-580, 2008.
27. Yu L, Wan F, Dutta S, et al: Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci USA 103: 4952-4957, 2006.
28. Ma WW and Adjei AA: Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59: 111-137, 2009.